E Fund Management Co. Ltd. Boosts Stock Position in Edwards Lifesciences Co. (NYSE:EW)

E Fund Management Co. Ltd. lifted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 63.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,846 shares of the medical research company’s stock after purchasing an additional 2,273 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $433,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Lindbrook Capital LLC lifted its position in Edwards Lifesciences by 12.9% in the fourth quarter. Lindbrook Capital LLC now owns 4,196 shares of the medical research company’s stock worth $311,000 after buying an additional 478 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Edwards Lifesciences in the fourth quarter worth $213,844,000. Proficio Capital Partners LLC bought a new stake in Edwards Lifesciences in the fourth quarter worth $8,456,000. M&T Bank Corp lifted its position in Edwards Lifesciences by 6.8% in the fourth quarter. M&T Bank Corp now owns 41,898 shares of the medical research company’s stock worth $3,102,000 after buying an additional 2,678 shares during the last quarter. Finally, Assetmark Inc. lifted its position in Edwards Lifesciences by 786.9% in the fourth quarter. Assetmark Inc. now owns 1,082 shares of the medical research company’s stock worth $80,000 after buying an additional 960 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $74.08, for a total value of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,739 shares of company stock worth $2,799,104 over the last quarter. Insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on EW. Barclays raised their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 13th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Citigroup lifted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group lifted their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research report on Thursday, February 13th. Finally, Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock opened at $70.36 on Friday. The stock’s fifty day moving average price is $72.26 and its 200-day moving average price is $70.38. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market cap of $41.37 billion, a P/E ratio of 10.10, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, equities research analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.